GOALS OF WORK: To make a descriptive analysis of clinical and laboratories parameters in advanced neoplastic patients. MATERIALS AND METHODS: We interviewed 406 terminally ill cancer patients to study demographic and neoplastic data, 24 graded symptoms, 21 analytical parameters and scales to evaluate general condition, quality of life and independence in daily activities. MAIN RESULTS: An average of 9.3 symptoms per patient were detected and median survival was 26.5 days. Most frequent symptoms were asthenia (96.8%), anorexia (94.8%), weight loss (88.1%) and pain (80.5%). Principal laboratory abnormalities were high blood sedimentation rate (96%), high cytolysis and cholestasis enzyme levels (50-77%), anemia (81.5%), low protein (66%) and low albumin levels (67%). Symptom prevalence was different according to age, gender, primary tumour, location of metastasis, laboratory parameters, performance status, quality of life or independence in daily-living activities. CONCLUSIONS: We should know more frequent symptoms affecting terminal cancer patients and any factor contributing to it to provide more comfort in the final phases of life.
GOALS OF WORK: To make a descriptive analysis of clinical and laboratories parameters in advanced neoplasticpatients. MATERIALS AND METHODS: We interviewed 406 terminally ill cancerpatients to study demographic and neoplastic data, 24 graded symptoms, 21 analytical parameters and scales to evaluate general condition, quality of life and independence in daily activities. MAIN RESULTS: An average of 9.3 symptoms per patient were detected and median survival was 26.5 days. Most frequent symptoms were asthenia (96.8%), anorexia (94.8%), weight loss (88.1%) and pain (80.5%). Principal laboratory abnormalities were high blood sedimentation rate (96%), high cytolysis and cholestasis enzyme levels (50-77%), anemia (81.5%), low protein (66%) and low albumin levels (67%). Symptom prevalence was different according to age, gender, primary tumour, location of metastasis, laboratory parameters, performance status, quality of life or independence in daily-living activities. CONCLUSIONS: We should know more frequent symptoms affecting terminal cancerpatients and any factor contributing to it to provide more comfort in the final phases of life.
Authors: Antonio Lobo; Lorenzo Chamorro; Antonio Luque; Rafael Dal-Ré; Xavier Badia; Eva Baró Journal: Med Clin (Barc) Date: 2002-04-13 Impact factor: 1.725
Authors: R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; E Kiyasu; K Sobel; N Coyle; N Kemeny; L Norton Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: Eefje M Sizoo; Lies Braam; Tjeerd J Postma; H Roeline W Pasman; Jan J Heimans; Martin Klein; Jaap C Reijneveld; Martin J B Taphoorn Journal: Neuro Oncol Date: 2010-01-27 Impact factor: 12.300
Authors: David S Hong; Goldy C George; Eucharia C Iwuanyanwu; Bahareh Tavana; Gerald S Falchook; Sarina A Piha-Paul; Jennifer J Wheler; Reena H Mistry; Xiudong Lei; Razelle Kurzrock Journal: J Cancer Res Clin Oncol Date: 2013-03-02 Impact factor: 4.553